Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus

BACKGROUND - Given the modest responses to everolimus, a mTOR inhibitor, in multiple tumor types, there is a pressing need to identify predictive biomarkers for this drug. Using targeted ultra-deep sequencing, we aimed to explore genomic alterations that confer extreme sensitivity to everolimus.

RESULTS - We collected formalin-fixed paraffin-embedded tumor/normal pairs from 39 patients (22 with exceptional clinical benefit, 17 with no clinical benefit) who were treated with everolimus across various tumor types (13 gastric cancers, 15 renal cell carcinomas, 2 thyroid cancers, 2 head and neck cancer, and 7 sarcomas). Ion AmpliSeqTM Comprehensive Cancer Panel was used to identify alterations across all exons of 409 target genes. Tumors were sequenced to a median coverage of 552x. Cancer genomes are characterized by 219 somatic single-nucleotide variants (181 missense, 9 nonsense, 7 splice-site) and 22 frameshift insertions/deletions, with a median of 2. 1 mutations per Mb (0 to 12. 4 mutations per Mb). Overall, genomic alterations with activating effect on mTOR signaling were identified in 10 of 22 (45%) patients with clinical benefit and these include MTOR, TSC1, TSC2, NF1, PIK3CA and PIK3CG mutations. Recurrently mutated genes in chromatin remodeling genes (BAP1; n = 2, 12%) and receptor tyrosine kinase signaling (FGFR4; n = 2, 12%) were noted only in patients without clinical benefit.

CONCLUSIONS - Regardless of different cancer types, mTOR-pathway-activating mutations confer sensitivity to everolimus. Targeted sequencing of mTOR pathway genes facilitates identification of potential candidates for mTOR inhibitors.

Oncotarget. 2016 Feb 07 [Epub ahead of print]

Sun Min Lim, Hyung Soon Park, Sangwoo Kim, Sora Kim, Siraj M Ali, Joel R Greenbowe, In Seok Yang, Nak-Jung Kwon, Jae Lyun Lee, Min-Hee Ryu, Jin-Hee Ahn, Jeeyun Lee, Min Goo Lee, Hyo Song Kim, Hyunki Kim, Hye Ryun Kim, Yong Wha Moon, Hyun Cheol Chung, Joo-Hang Kim, Yoon-Koo Kang, Byoung Chul Cho

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. , Department of Pharmacology and Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea. , Severance Biomedical Science Institute and Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea. , Severance Biomedical Science Institute and Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea. , Foundation Medicine Inc, Cambridge, MA, USA. , Foundation Medicine Inc, Cambridge, MA, USA. , Severance Biomedical Science Institute and Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea. , MacroGen Inc. , Seoul, Korea. , Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. , Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. , Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. , Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. , Department of Pharmacology and Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea. , Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. , Department of Pathology, Yonsei University College of Medicine, Seoul, Korea. , Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. , Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. , Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. , Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea. , Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. , Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe